Indeed, now is the moment to step on the gas in biotech. The past 15 years have been nothing short of extraordinary in the field. We finally have the tools needed to effectively measure biology, manipulate biology, and increasingly predict biology. More recently, we have been able to turn more and more problems into computational problems.
With all of this coming together, we should be accelerating both public and private investment in biotechnology because we're getting closer and closer to transformative therapies. But...we're failing to rise to the occasion and meet the moment.
The entire class of "biologics" drugs only came about in the past 15 years thanks to advances in sequencing and biotech. They are the mainstays of treatment for dozens of serious dermatologic, rheumatologic, and GI diseases, not to mention they directly cured multiple cancers.
Not op, but I’m in the field and can give you some things to read about:
- CAR-T
- CRISPR
- PRIME editing
- Base editing
- Modified mRNA
- PD-1 inhibitors
- On the cusp of personalized cancer vaccines
- ADCs
- Structure correctors
- Targeted protein degraders
- siRNAs
These have all really hit their stride in the past 15 years. Guess where all of them initially came from? Random ass government-funded academic research. Sure, you can split hairs with me on the 15 years and NIH/NSF etc funding, but it’s basically true. We are killing the golden goose…
Delivery vectors for nucleic acid have really progressed too. Peptide design and screening (also high throughput tools in general) have developed and led to great advances in peptide conjugates, such as peptide radioligands.
Sorry, I am not involved with biotech. Genuinely curious.
Edit. My impression of bio tech is that upfront costs are high and timeline for commercialization is long, and the only real biotech firm that I am aware of is Theranos. So I am probably coming from a place of ignorance.
With all of this coming together, we should be accelerating both public and private investment in biotechnology because we're getting closer and closer to transformative therapies. But...we're failing to rise to the occasion and meet the moment.